UBS analyst Timothy Arcuri maintains Applied Materials (NASDAQ:AMAT) with a Neutral and raises the price target from $90 to $98.
ResMed Q2 Adj. EPS $1.47 Misses $1.52 Estimate, Sales $894.90M Miss $935.25M Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $1.47 per share which missed the analyst consensus estimate of $1.52 by 3.29 percent. This is a 4.26 percent increase over earnings of $1.41 per share from the same period
